Core Insights - Transgene is advancing its individualized neoantigen therapeutic vaccine, TG4050, which has shown durable clinical outcomes in head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapse [1][4][6] - The company has sufficient financial resources to support its operations until early 2028, following a successful fundraising of approximately €105 million and the conversion of €39 million debt into shares [21][26] - The randomized Phase 2 part of the clinical trial for TG4050 is nearing completion, with the primary endpoint being two-year disease-free survival [10][11] Clinical Development - TG4050 has demonstrated a 100% disease-free survival rate after more than two years of follow-up in the Phase 1 trial, meeting all trial endpoints [7][8] - A new Phase 1 trial for a second indication in operable solid tumors is planned to start in 2026, reflecting the strategy to expand the clinical evaluation of the myvac® platform [2][12] - Positive results from the Phase 1 trial of BT-001 support further clinical development, showing antitumoral activity in patients with advanced refractory tumors [15][17] Financial Performance - Operating revenue for 2025 was €7.2 million, an increase from €6.4 million in 2024, primarily driven by research tax credits [22][43] - The company reported a net loss of €37.5 million in 2025, compared to a net loss of €34.0 million in 2024, with a net cash burn of €38.2 million [26][48][50] - Cash, cash equivalents, and other financial assets totaled €111.9 million as of December 31, 2025, significantly up from €16.7 million at the end of 2024 [26][49] Strategic Initiatives - Transgene is optimizing its manufacturing processes to prepare for potential pivotal clinical trials [13] - The company is leveraging its proprietary VacDesignR® computational tool to enhance the quality and reliability of its vaccine production [14] - Recent leadership additions aim to accelerate the development of the myvac® platform, with new appointments in key executive roles [19][20]

Core Viewpoint - Transgene has strengthened its Scientific Advisory Board by appointing two prominent scientific advisors, Prof. Antoine Italiano and Prof. Ignacio Melero, to enhance its leadership in cancer immunotherapy development [1][2]. Group 1: Company Overview - Transgene is a biotechnology company focused on designing and developing virus-based immunotherapies for cancer treatment, with a clinical-stage portfolio that includes the myvac® platform for individualized neoantigen therapeutic vaccines [10][11]. - The company’s lead asset, TG4050, has shown proof of principle in patients for the adjuvant treatment of head and neck cancers, and it is also developing other viral vector-based assets like BT-001 [10]. Group 2: Scientific Advisors - Prof. Antoine Italiano is a leading medical oncologist with expertise in early drug development and precision medicine, serving as Head of the Department of Medicine at Institut Bergonié and leading the Precision Medicine program at Gustave Roussy [2][3]. - He has been the Principal Investigator for over 50 Phase I trials and more than 40 Phase II and III clinical trials, focusing on immuno-oncology and targeted therapies [3][4]. - Prof. Ignacio Melero is a professor of immunology at the University of Navarra and co-director of the Department of Immunology and Immunotherapy, recognized for his work in cancer immunotherapy and immunostimulatory monoclonal antibodies [5][6]. - He has led over 40 clinical trials in immunotherapy and has published more than 350 scientific articles, receiving an ERC Advanced Grant for his research on mRNA-based immunotherapies [7][8].

Core Insights - TG4050 demonstrates strong potential as an individualized cancer immunotherapy, showing 100% two-year disease-free survival in patients with operable head and neck cancers [3][5][8] Clinical Trial Results - The Phase I/II trial of TG4050 involved patients with HPV-negative head and neck squamous cell carcinoma (HNSCC), where one-third of patients typically experience recurrence within two years post-surgery [3] - Half of the participants received TG4050 immediately after primary adjuvant treatment, while the other half received it at the time of disease recurrence [4][16] - The trial results indicate that TG4050 can prevent cancer relapses when used as monotherapy in high-risk, resected, locally advanced HPV-negative HNSCC patients [5] Immunogenicity and T-cell Responses - TG4050 induced neoantigen-specific T-cell responses in 73% of evaluable patients, with these responses being durable for up to one year post-treatment [6][7] - The vaccine was well-tolerated, showing no unexpected safety signals, reinforcing its potential for further development [5][8] Publication and Transparency - The results of the Phase I trial have been published on medRxiv, emphasizing the company's commitment to transparency and scientific rigor [2][8] - The findings are currently under evaluation for publication in a peer-reviewed journal [2] Future Developments - TG4050 is undergoing further evaluation in a randomized Phase I/II clinical trial (NCT04183166), with first immunogenicity data from the Phase II part expected in the second half of 2026 [7][16]

Core Points - Transgene successfully raised approximately €105 million through a fundraising initiative involving private placements and retail offerings at a price of €1.02 per share [1][6][10] - The funds will primarily support the development of the myvac® platform, which focuses on individualized therapeutic vaccines for cancer treatment [4][5][7] - The fundraising included participation from specialized healthcare investors and existing shareholders, indicating strong institutional interest [2][21] Fundraising Details - The fundraising consisted of a private placement and a public offering via the PrimaryBid platform, with a total of 141,433,349 new ordinary shares issued, representing 106.5% of the company's current share capital [9][10] - The subscription price of €1.02 per share reflects a 25% discount compared to the closing price prior to the fundraising [10] - A reserved capital increase of €39,262,015.44 was also conducted for TSGH, utilizing amounts advanced under a current account advance agreement [3][12] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing Phase 2 trials and the launch of new indications [7][5] - About 20% will be directed towards R&D costs related to the myvac® program and other clinical trials [7] - The remaining funds will cover general administrative expenses and recurring cash consumption [7] Expected Milestones - Key milestones include the completion of the ongoing Phase 2 trial in head and neck cancers, with results anticipated by late 2027 or early 2028 [4][15] - The company plans to launch a Phase 1 trial in a new indication and prepare for pivotal trials by the end of 2027 [15][4] Share Capital and Ownership Structure - Post-fundraising, the company's share capital will amount to €82,256,012.70, divided into 274,186,709 ordinary shares [18] - TSGH will hold 78.29% of the capital, while SITAM Belgium will hold 3.55%, with other shareholders comprising 18.16% [18][21] Trading and Regulatory Information - Trading of Transgene's shares on Euronext Paris was suspended during the fundraising and is set to resume on November 27, 2025 [23][24] - The new shares will be fungible with existing shares and will carry the same rights [25]

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris starting November 26, 2025, pending the announcement of its capital increase results [1] - Trading is expected to resume on November 27, 2025, at market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies in clinical development [2] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [2] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [2] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [3] - The invir.IO® platform allows for the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the publication of results from its capital increase [1] - Trading is expected to resume on November 27, 2025, at the market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment [2] - The company's lead candidate, TG4050, is an individualized treatment that has shown clinical proof of concept in patients with head and neck cancer [2] - Transgene is also developing other candidates, including BT-001, which is based on a patented oncolytic virus [2] Technology Platforms - The myvac® platform allows for patient-specific immunotherapy by integrating tumor mutations identified through artificial intelligence [3] - The invir.IO® platform enables the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Viewpoint - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the announcement of its capital increase results, with trading expected to resume on November 27, 2025 [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies currently in clinical development [3] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [3] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [3] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [4] - The invir.IO® platform allows for the design of a new generation of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [4]

Core Insights - Transgene is set to present its proprietary computational tool, VacDesignR®, at the ESMO AI & Digital Oncology 2025 conference, which enhances the design and production of recombinant Modified Vaccinia Ankara (MVA)-based vectors for individualized neoantigen therapeutic vaccines [1][2][5] Group 1: VacDesignR® Tool - VacDesignR® optimizes recombinant plasmid architecture for MVA vectors, improving production reliability and vector quality by minimizing unwanted homologous recombination and intelligently selecting peptide sequences [3] - Future versions of VacDesignR® will integrate AI components to enhance performance and scalability, aligning with Transgene's strategy to expedite production timelines for individualized therapeutic vaccines [4] Group 2: Clinical Development - The individualized immunotherapies developed through the myvac® platform are currently in a Phase I/II clinical trial (NCT04183166), utilizing the VacDesignR® tool for their design [2] - TG4050, the first individualized therapeutic vaccine based on the myvac® platform, is designed to treat HPV-negative head and neck cancers following surgery and adjuvant therapy [4][8] Group 3: Company Overview - Transgene focuses on designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes viral vector-based immunotherapeutics [8] - The myvac® platform allows for the creation of personalized immunotherapies that encode patient-specific mutations, utilizing advanced AI technologies [9]

Core Insights - TG4050 demonstrates the ability to induce neoantigen-specific cytotoxic CD8+ T cell responses, which can target and eliminate tumor cells, potentially reducing the risk of cancer relapse [1][3][4] Company Overview - Transgene is a biotech company focused on developing virus-based immunotherapies for cancer treatment, with TG4050 being its lead asset [9][12] - TG4050 is an individualized therapeutic vaccine based on the myvac® platform, designed to stimulate the immune system to recognize and destroy tumor cells [10][12] Clinical Development - TG4050 is currently being evaluated in a Phase I/II clinical trial for patients with HPV-negative head and neck cancers, with the first immunogenicity data from the Phase II part expected in the second half of 2026 [14] - The trial includes a randomized study design, assessing the treatment benefits of TG4050 in patients at risk of relapse [14] Immunological Data - New immunological data presented at the SITC Annual Meeting confirm TG4050's mechanism of action and its potential for sustained prevention of cancer relapses [4][5] - CD8+ T cells induced by TG4050 exhibit an effector phenotype and persist for up to two years post-treatment, indicating long-term immune response capabilities [8][5] Collaboration and Technology - Transgene collaborates with NEC Corporation, leveraging NEC's AI-driven platform to enhance the development of individualized neoantigen therapeutic vaccines [5][12] - NEC's Neoantigen Prediction System utilizes advanced AI to identify and select the most immunogenic sequences for the vaccine [15][12]

Core Insights - Transgene will present a detailed analysis of the neoantigen-specific T cell response from the Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the upcoming SITC Annual Meeting [1][3] - TG4050 is being developed for solid tumors, specifically targeting HPV-negative head and neck cancers, utilizing Transgene's myvac® technology and NEC's AI capabilities [3][5] - The Phase I trial results showed that all patients receiving TG4050 remained disease-free after a minimum of 2-year follow-up, contrasting with a 19% relapse rate in the observational arm [4] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics [5] - TG4050 is the lead asset of the company, representing the first individualized therapeutic vaccine based on the myvac® platform, demonstrating proof of principle in head and neck cancer treatment [5][6] - The company is also advancing other viral vector-based assets, including BT-001, which is in clinical development [5] Clinical Development - TG4050 is currently being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers [3] - A Phase II extension of the trial is ongoing, with patient enrollment currently in progress [4]